Chronic myeloid leukemia (CML) represents a success in precision oncology, defined by the presence of the BCR-ABL1 fusion gene, which encodes a constitutively active tyrosine kinase that drives malignant transformation [1,86]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.